Functional roles for PECAM-1 (CD31) and VE-cadherin (CD144) in tube assembly and lumen formation in three-dimensional collagen gels.
Various in vitro models have been described that emulate one or more of the processes involved in angiogenesis in vivo. In the present study endothelial cells were cultured in three-dimensional type I collagen lattices in the presence of a mixture of basic fibroblast growth factor, vascular endothelial cell growth factor, and phorbol myristate acetate. Under these conditions, the endothelial cells rapidly assemble into an interconnected network of tube-like structures with a high frequency of intercellular canals or lumens. The formation of the networks and lumens was completely blocked by cycloheximide and by actinomycin D. Monoclonal antibodies directed against CD31 or vascular endothelial cadherin (VE-cadherin) inhibited the formation of endothelial tubes. A subtle difference in the morphology of cells treated with anti-CD31 versus anti-VE-cadherin was noted; namely, cells incubated in the presence of CD31 antibodies were rounded or formed attenuated tube-like structures, both of which were characterized by a single, large intra- or intercellular vacuole. In contrast, tube formation by cells incubated in the presence of VE-cadherin antibodies was also impaired and, most notably, demonstrated a reduction in either vacuole formation or vacuole fusion, depending upon the monoclonal antibody used. We suggest that the two endothelial-junction-associated proteins, CD31 and VE-cadherin, play different roles in the process of tube formation. CD31 appears to be required for cell elongation, migration, and/or invasion in the gels as well as for cell-cell association to form the network structures. VE-cadherin also appears to be required for cell-cell association, but additionally appears to play some role in the process of vacuolization or vacuole fusion leading to intercellular lumen formation.
Yang
S
S
Department of Cardiovascular Research, Genentech Inc., South San Francisco, California, USA.
Graham
J
J
Kahn
J W
JW
Schwartz
E A
EA
Gerritsen
M E
ME
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D015703:Antigens, CD; D015820:Cadherins / Q000502:physiology*; D002196:Capillaries / Q000166:cytology / Q000254:growth & development; D002460:Cell Line; D003094:Collagen / Q000378:metabolism; D003513:Cycloheximide / Q000494:pharmacology; D003609:Dactinomycin / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects; D005452:Fluoresceins; D005456:Fluorescent Dyes; D005782:Gels; D006801:Humans; D018919:Neovascularization, Physiologic / Q000187:drug effects / Q000502:physiology*; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000502:physiology*; D014176:Protein Biosynthesis; D012333:RNA, Messenger / Q000096:biosynthesis; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D013997:Time Factors; D014617:Vacuoles / Q000502:physiology; D000099152:Cadherin 5
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D015820:Cadherins; D003094:Collagen; D003513:Cycloheximide; D003609:Dactinomycin; D005452:Fluoresceins; D005456:Fluorescent Dyes; D005782:Gels; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D012333:RNA, Messenger; D013755:Tetradecanoylphorbol Acetate; D000099152:Cadherin 5; C024098:6-carboxyfluorescein